CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
empagliflozin/linagliptin FDCdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02815644
NCT02815644Phase 1Completed
CompareCT.gov

Investigation of the Effect of Food on the Bioavailability of Empagliflozin / Linagliptin Fixed Dose Combination Tablet in an Open, Randomised, Single Dose, Two Way Cross-over Study in Healthy Japanese Male Subjects

Boehringer Ingelheim·interventional·Posted Jun 28, 2016·Updated Aug 16, 2018

In Brief

A Phase 1 clinical trial evaluating empagliflozin/linagliptin FDC for Healthy. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The trial will be performed as an open-label, randomised, single-dose, two-sequence crossover design for the assessment of effect of food on bioavailability of empagliflozin / linagliptin fixed dose combination (FDC) tablet.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 28, 2016
Enrollment StartJul 15, 2016
Primary CompletionOct 5, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.0 years ago

Interventions

empagliflozin/linagliptin FDCdrug

empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet